-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NBTXR-3 in Metastatic Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Metastatic Liver Cancer Drug Details: NBTXR-3 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-039 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-039 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-039 in Diffuse Large B-Cell Lymphoma Drug Details: CCAR-039 is...
-
Product Insights
NewHypopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Hypopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end...
-
Product Insights
NewLaryngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Laryngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Laryngeal cancer is a disease in which malignant (cancer) cells form in the tissues of the larynx. Most laryngeal cancers form in squamous cells, the thin, flat cells lining the inside of the larynx. Symptoms include persistent hoarseness, difficulty swallowing, sore throat, or a lump in the neck. Treatment involves a combination of surgery, radiation therapy, and chemotherapy. Early detection is crucial...
-
Product Insights
NewOropharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Oropharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which...
-
Product Insights
NewRecurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent head and neck squamous cell carcinoma (HNSCC) refers to the return of cancer in the head and neck region after initial treatment. HNSCC includes tumors of the oral cavity, pharynx, larynx, and other structures. Recurrence can occur locally, regionally, or distantly. Management of recurrent HNSCC depends on the specific circumstances, including the location and extent...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...